Galmed Pharmaceuticals (GLMD) EPS (Diluted) Growth (3y) (2016 - 2025)
Galmed Pharmaceuticals (GLMD) EPS (Diluted) Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 61.64% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 36.83% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.90% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.81% |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -99.54% |
| Jun 30, 2023 | 25.99% |
| Sep 30, 2022 | -100.67% |
| Jun 30, 2022 | 140.08% |
| Sep 30, 2021 | -42.62% |
| Mar 31, 2021 | 40.52% |
| Dec 31, 2020 | -315.65% |
| Sep 30, 2020 | 339.13% |
| Jun 30, 2020 | -46.13% |
| Mar 31, 2020 | -63.80% |
| Dec 31, 2019 | 115.09% |
| Sep 30, 2019 | -26.03% |
| Jun 30, 2019 | -26.03% |
| Mar 31, 2019 | -26.09% |
| Dec 31, 2018 | -10.89% |
| Sep 30, 2018 | -45.17% |
| Jun 30, 2018 | -26.04% |
| Mar 31, 2018 | -79.10% |
| Jun 30, 2017 | 8.11% |
| Mar 31, 2017 | -58.01% |